Lekoklar

Clarithromycin, the active ingredient in Lekoklar, is a macrolide antibiotic presented as an oral tablet for oral use. It treats bacterial infections such as community‑acquired pneumonia, acute sinusitis, bronchitis exacerbations, skin infections, and is used in combination regimens for Helicobacter pylori eradication.

GNH USA supplies Lekoklar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, and clinics worldwide, ensuring quality manufacturing, regulatory compliance, and reliable distribution across multiple regions. The company adheres to EU GMP standards and provides comprehensive technical support for product integration.

Clarithromycin is a macrolide antibiotic that targets bacterial infections of the respiratory and gastrointestinal tracts.

Community‑acquired pneumonia: effective in eradicating the causative bacteria and improving clinical outcomes. Acute bacterial sinusitis: reduces infection severity and accelerates symptom resolution. Helicobacter pylori eradication (in combination therapy): contributes to bacterial clearance as part of triple‑therapy regimens.

Clarithromycin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild stomach upset. - Diarrhea: loose stools. - Taste disturbance: altered taste perception.

Serious or Rare Side Effects: - Severe allergic reactions (anaphylaxis): potentially life‑threatening hypersensitivity. - QT interval prolongation: risk of cardiac arrhythmia. - Hepatotoxicity: liver enzyme elevation or injury.

Before prescribing Lekoklar, clinicians should consider several safety measures.

Assess renal and hepatic function before initiating therapy. Avoid use in patients with known macrolide hypersensitivity. Monitor cardiac status in patients with arrhythmia risk. Consider drug‑drug interaction potential, especially with CYP3A4 substrates. Use with caution in pregnancy and breastfeeding due to limited data. Store at ambient temperature (below 25°C): keep in original packaging, protect from moisture.

Clarithromycin interacts with several medicines; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid): - Concurrent use with strong CYP3A4 inhibitors (e.g., ketoconazole) may cause toxicity. - Co‑administration with drugs that prolong QT interval (e.g., cisapride) increases risk of arrhythmia. - Combination with colchicine can lead to severe toxicity.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin) may reduce clarithromycin levels. - Warfarin may have increased anticoagulant effect. - Statins metabolized by CYP3A4 (e.g., simvastatin) may have increased risk of myopathy.